

James A Reiffel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/241578/publications.pdf>

Version: 2024-02-01

160
papers

4,354
citations

147801

31
h-index

114465

63
g-index

160
all docs

160
docs citations

160
times ranked

4905
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictors of dronedarone plasma drug concentrations and effect on atrial fibrillation/atrial flutter recurrence: Analyses from the EURIDIS and ADONIS studies. <i>Clinical Cardiology</i> , 2022, 45, 119-128.	1.8	0
2	Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS&ADONIS trials. <i>Clinical Cardiology</i> , 2022, 45, 101-109.	1.8	1
3	OUP accepted manuscript. <i>Europace</i> , 2022, , .	1.7	1
4	Selected Advancements in the Management of Atrial Fibrillation from the Year 2021. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2022, 13, 4840-4846.	0.5	2
5	Understanding Antiarrhythmic Drug Efficacy for the Clinical Practitioner: There Is More than Meets the Eye. <i>American Journal of Medicine</i> , 2022, 135, 822-827.	1.5	2
6	AIM&AF: A Physician Survey in the United States and Europe. <i>Journal of the American Heart Association</i> , 2022, 11, e023838.	3.7	10
7	Atrial Fibrillation: Is Rhythm Control Required, and If So, How, and What Is the Internist's Role?. <i>American Journal of Medicine</i> , 2022, 135, 939-944.	1.5	1
8	Drug Interactions Affecting Antiarrhythmic Drug Use. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, 15, 101161CIRCEP121007955.	4.8	6
9	The safety of flecainide for atrial fibrillation in patients with stable coronary artery disease " Fact or fallacy. <i>American Heart Journal</i> , 2022, 248, 163-164.	2.7	1
10	Drug Interactions Affecting Oral Anticoagulant Use. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, 15, .	4.8	13
11	Guidelines Are Meant to Guide, But They Are Not Absolute. <i>American Journal of Medicine</i> , 2022, 135, e132.	1.5	0
12	Patterns of oral anticoagulation use with cardioversion in clinical practice. <i>Heart</i> , 2021, 107, 642-649.	2.9	3
13	"Pill in the Pocket" Antiarrhythmic Drugs for Orally Administered Pharmacologic Cardioversion of Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2021, 140, 55-61.	1.6	9
14	Use of the HAVOC Score to Identify Patients at Highest Risk of Developing Atrial Fibrillation. <i>Cardiology</i> , 2021, 146, 633-640.	1.4	4
15	When the time in the therapeutic range falls short: out of range values can be of importance. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e20-e20.	3.0	0
16	Relation of Antecedent Symptoms to the Likelihood of Detecting Subclinical Atrial Fibrillation With Inserted Cardiac Monitors. <i>American Journal of Cardiology</i> , 2021, 145, 64-68.	1.6	3
17	When two is not better than one: the amalgamation of atrial fibrillation and chronic obstructive pulmonary disease. <i>European Heart Journal</i> , 2021, 42, 3555-3557.	2.2	1
18	Letter by Reiffel Regarding Article, "Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative". <i>Circulation</i> , 2021, 144, e160.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Clinicians May Disagree About the Usefulness of the Physical Exam, but Those Who Refute It Are Wrong. <i>American Journal of Medicine</i> , 2021, 134, e496.	1.5	1
20	Risk of Major Bleeding in Patients With Atrial Fibrillation Taking Dronedaron in Combination With a Direct Acting Oral Anticoagulant (From a U.S. Claims Database). <i>American Journal of Cardiology</i> , 2021, 159, 79-86.	1.6	7
21	The Importance Of Atrial Fibrillations Associated Comorbidities as Clinical Presentation and Outcome Contributors. <i>Journal of Atrial Fibrillation</i> , 2021, 14, 20200517.	0.5	0
22	Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. <i>American Heart Journal</i> , 2020, 220, 145-154.	2.7	3
23	Rhythm monitoring strategies in patients at high risk for atrial fibrillation and stroke: A comparative analysis from the REVEAL AF study. <i>American Heart Journal</i> , 2020, 219, 128-136.	2.7	12
24	Propensity Score Matching: The “Devil is in the Details” Where More May Be Hidden than You Know. <i>American Journal of Medicine</i> , 2020, 133, 178-181.	1.5	58
25	Could Different Thresholds for Tachycardic-Induced Atrial Myopathy Reflect Different Rates Between Atrial Fibrillation and Flutter?. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2179.	2.8	0
26	Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e007775.	4.8	6
27	The high road, the low road, and no road: She took them all. <i>Journal of Electrocardiology</i> , 2020, 60, 175-176.	0.9	0
28	Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008274.	3.9	1
29	Shared decision-making in atrial fibrillation: patient-reported involvement in treatment decisions. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020, 6, 263-272.	4.0	16
30	Sinus node depolarization “Present during all sinus rhythms but never seen on the 12-lead ECG: An illustrative case-report that provides its recording. <i>Journal of Electrocardiology</i> , 2020, 60, 192-194.	0.9	0
31	QT Interval Abnormalities with Pulmonary Emboli. <i>American Journal of Medicine</i> , 2020, 133, e113.	1.5	0
32	Dronedaron treatment following cardioversion in patients with atrial fibrillation/flutter: A post hoc analysis of the EURIDIS and ADONIS trials. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 1022-1030.	1.7	3
33	Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. <i>Heart</i> , 2020, 106, 358-364.	2.9	16
34	Detection of Previously Unrecognized (Subclinical) Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2020, 127, 169-175.	1.6	6
35	The Link Between CHA ₂ DS ₂ -VASc Score and Thromboembolic Risk in Patients Without Known Atrial Fibrillation: Are We Missing a Silent Culprit?. <i>Journal of Atrial Fibrillation</i> , 2020, 12, 2303.	0.5	2
36	Pharmacologic Management of Atrial Fibrillation and Flutter. <i>Contemporary Cardiology</i> , 2020, , 359-407.	0.1	0

#	ARTICLE	IF	CITATIONS
37	The Interaction Among Atrial Thromboembolism, Atrial Fibrillation, and Atrial Cardiomyopathy. American Journal of Cardiology, 2019, 124, 1317.	1.6	4
38	Changes in Management Following Detection of Previously Unknown Atrial Fibrillation by an Insertable Cardiac Monitor (from the REVEAL AF Study). American Journal of Cardiology, 2019, 124, 864-870.	1.6	4
39	Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. JAMA Cardiology, 2019, 4, 756.	6.1	10
40	When an Omission Alters the Message, Missing Facts Must be Added. American Journal of Medicine, 2019, 132, e722.	1.5	0
41	Biomarkers and their relationship to atrial fibrillation: mechanisms, prognosis and management. Biomarkers in Medicine, 2019, 13, 1433-1438.	1.4	2
42	Mass Screening for Atrial Fibrillation: The Hype, The Methods, and The Application. American Journal of Medicine, 2019, 132, 668-670.	1.5	4
43	Defining Clinically Important Difference in the Atrial Fibrillation Effect on Quality-of-Life Score. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005358.	2.2	59
44	Reader's Comments: Beyond Atrial Fibrillation Patterns as Contributors to Risk of Thromboembolism. American Journal of Cardiology, 2019, 124, 166.	1.6	1
45	Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2019, 321, 1261.	7.4	953
46	Searching for Atrial Fibrillation Poststroke. Circulation, 2019, 140, 1834-1850.	1.6	184
47	Apples will never be oranges, but when you go fishing you may get a bite. International Journal of Cardiology, 2019, 278, 155-156.	1.7	0
48	TTR: Time in Therapeutic Range or "The Troublesome Report". Journal of Innovations in Cardiac Rhythm Management, 2019, 10, 3469-3470.	0.5	1
49	Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation. Circulation, 2018, 138, 889-897.	1.6	23
50	An Incomplete Story. Journal of the American College of Cardiology, 2018, 71, 104.	2.8	0
51	Embolic and Other Adverse Outcomes in Symptomatic Versus Asymptomatic Patients With Atrial Fibrillation (from the ORBIT-AF Registry). American Journal of Cardiology, 2018, 122, 1677-1683.	1.6	13
52	Letter by Reiffel Regarding Article, "Unique ECG During Sinus Rhythm in a Patient With A Postmyocardial Infarction-Sustained Ventricular Tachycardia". Circulation, 2018, 138, 328-329.	1.6	0
53	Letter by Reiffel Regarding Article, "Treatment of Subclinical Atrial Fibrillation: Does One Plus One Always Equal Two?". Circulation, 2018, 138, 122-123.	1.6	0
54	Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. Heart, 2018, 104, 1850-1858.	2.9	23

#	ARTICLE	IF	CITATIONS
55	Propensity-Score Matching: Optimal, Adequate, or Incomplete?. <i>Journal of Atrial Fibrillation</i> , 2018, 11, 2130.	0.5	22
56	Abstract 189: Identifying Patients at Highest Risk of Developing Atrial Fibrillation and the Role of Remote Prior Stroke: Insights From the REVEAL AF Study. <i>Stroke</i> , 2018, 49, .	2.0	1
57	Considerations Regarding the Periprocedural Use of Oral Anticoagulation Therapy in Patients Undergoing Atrial Fibrillation Ablation. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2018, 9, 3282-3283.	0.5	0
58	Abnormal ECG, Seizures, and Associated Neurological Deficits. <i>Circulation</i> , 2017, 135, 490-491.	1.6	0
59	Long-term electrocardiographic safety monitoring in clinical drug development: A report from the Cardiac Safety Research Consortium. <i>American Heart Journal</i> , 2017, 187, 156-169.	2.7	11
60	Time in the Therapeutic Range for Patients Taking Warfarin in Clinical Trials. <i>Circulation</i> , 2017, 135, 1475-1477.	1.6	46
61	To the Editorâ€” Minimal QT, not just maximal, may underlie TdP risk in women. <i>Heart Rhythm</i> , 2017, 14, e51.	0.7	0
62	The R-Wave Sign as a Predictor of Ventricular Tachyarrhythmias in Brugada Syndrome: The Criteria Need Verification and Clarification. <i>American Journal of Cardiology</i> , 2017, 120, 2299.	1.6	0
63	Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk Population. <i>JAMA Cardiology</i> , 2017, 2, 1120.	6.1	200
64	Pills Never Work in the Bottle. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1584-1586.	2.8	1
65	Selective Reporting: Silent Atrial Fibrillation and Cryptogenic Strokes. <i>American Journal of Medicine</i> , 2017, 130, e403.	1.5	0
66	Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, .	4.8	29
67	Time to Revisit the Time in the Therapeutic Range. <i>Journal of Atrial Fibrillation</i> , 2017, 9, 1569.	0.5	6
68	Optimum Risk Assessment for Stroke in Atrial Fibrillation: Should We Hold the Status Quo or Consider Magnitude Synergism and Left Atrial Appendage Anatomy?. <i>Arrhythmia and Electrophysiology Review</i> , 2017, 6, 161.	2.4	11
69	Time in the Therapeutic Range (TTR): An Overly Simplified Conundrum. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2017, 8, 2643-2646.	0.5	15
70	When Silence Isnâ€™t Golden: The Case of â€œSilentâ€•Atrial Fibrillation. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2017, 8, 2886-2893.	0.5	3
71	Baseline Demographics, Safety, and Patient Acceptance of an Insertable Cardiac Monitor for Atrial Fibrillation Screening: The REVEAL-AF Study. <i>Journal of Atrial Fibrillation</i> , 2017, 9, 1551.	0.5	7
72	Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2597-2604.	2.8	401

#	ARTICLE	IF	CITATIONS
73	If it were only that simple. <i>European Heart Journal</i> , 2016, 37, 1603-1605.	2.2	18
74	Patient factors associated with quality of life in atrial fibrillation. <i>American Heart Journal</i> , 2016, 182, 135-143.	2.7	62
75	Rhythm Control Versus Rate Control and Clinical Outcomes in Patients With Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 221-229.	3.2	33
76	The HARMONY Trial. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 1048-1056.	4.8	129
77	Editorial (Thematic Issue: Advances in The Therapy of Atrial Fibrillation: Incrementally Progressive But) Tj ETQq1 1 0,784314 rgBT /Ove	1.5	8
78	Novel Oral Anticoagulants. <i>American Journal of Medicine</i> , 2014, 127, e16-e17.	1.5	8
79	Atrial Fibrillation and Stroke: Epidemiology. <i>American Journal of Medicine</i> , 2014, 127, e15-e16.	1.5	73
80	Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <i>American Heart Journal</i> , 2014, 167, 735-742.e2.	2.7	120
81	New versus Traditional Approaches to Oral Anticoagulation in Patients with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2014, 127, e15.	1.5	3
82	Rationale and design of REVEAL AF: A prospective study of previously undiagnosed atrial fibrillation as documented by an insertable cardiac monitor in high-risk patients. <i>American Heart Journal</i> , 2014, 167, 22-27.	2.7	32
83	Are we at the Goal Line with the Novel Oral Anticoagulants and Have We Reached the End of the Line for Dronedaron and Vernakalant " or is There More to Come?. <i>Current Cardiology Reviews</i> , 2014, 10, 315-316.	1.5	0
84	Abstract 15680: Sinus Node Dysfunction in Associated With Higher Symptom Burden and Increased Risk of Progression to Permanent Atrial Fibrillation: Results From ORBIT-AF Registry. <i>Circulation</i> , 2014, 130, .	1.6	0
85	Rate versus rhythm control for management of atrial fibrillation in clinical practice: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. <i>American Heart Journal</i> , 2013, 165, 622-629.	2.7	61
86	Provider Specialty and Atrial Fibrillation Treatment Strategies in United States Community Practice: Findings From the ORBIT-AF Registry. <i>Journal of the American Heart Association</i> , 2013, 2, e000110.	3.7	60
87	Dronedaron: Where Does it Fit in the AF Therapeutic Armamentarium?. <i>Journal of Atrial Fibrillation</i> , 2013, 5, 752.	0.5	0
88	The Concept of "Burden" in Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , 2012, 4, 400.	0.5	1
89	The Use of Ranolazine in the Management of Recurrent Atrial Fibrillation After Percutaneous Radiofrequency Ablation. <i>Journal of Atrial Fibrillation</i> , 2012, 5, 562.	0.5	2
90	An important indirect drug interaction between dronedaron and warfarin that may be extrapolated to other drugs that can alter gastrointestinal function. <i>American Heart Journal</i> , 2011, 161, e5.	2.7	7

#	ARTICLE	IF	CITATIONS
91	Atrial Fibrillation: What Have Recent Trials Taught Us Regarding Pharmacologic Management of Rate and Rhythm Control?. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 247-259.	1.2	12
92	Does a Brugada Pattern ECG Precipitated by Excessive-Dose Flecainide Provide a Diagnosis of a Brugada Syndrome Patient and/or Contraindicate Its Use?. Circulation: Arrhythmia and Electrophysiology, 2011, 4, e47-51.	4.8	7
93	Pharmacologic Management of Atrial Fibrillation and Flutter. , 2011, , 165-193.		0
94	Practice Patterns Among United States Cardiologists for Managing Adults With Atrial Fibrillation (from the AFFECTS Registry). American Journal of Cardiology, 2010, 105, 1122-1129.	1.6	45
95	Warfarin and Aspirin Use in Atrial Fibrillation Among Practicing Cardiologist (from the AFFECTS) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.6	30
96	Frequency of Serious Arrhythmias Detected With Ambulatory Cardiac Telemetry. American Journal of Cardiology, 2010, 105, 1313-1316.	1.6	9
97	Efficacy and Safety of Prescription Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2010, 304, 2363.	7.4	183
98	Chronic Maintenance of Sinus Rhythm in Patients with Atrial Fibrillation Using Antiarrhythmic Drugs: Update 2010. Cardiac Electrophysiology Clinics, 2010, 2, 409-418.	1.7	1
99	The Conversion of Paroxysmal or Initial Onset Atrial Fibrillation with Oral Ranolazine: Implications for a New "Pill-In-Pocket" Approach in Structural Heart Disease. Journal of Atrial Fibrillation, 2010, 2, .	0.5	9
100	The Utility of Ambulatory Electrocardiographic Monitoring for Detecting Silent Arrhythmias and Clarifying Symptom Mechanism in an Urban Elderly Population with Heart Failure and Hypertension: Clinical Implications. Journal of Atrial Fibrillation, 2010, 3, 193.	0.5	11
101	The Power of One: a Highly Detailed, Log-Based, Case Example that Clearly Demonstrates the Effective Use of Ranolazine for the Control of Progressive Atrial Fibrillation. Journal of Atrial Fibrillation, 2010, 3, 304.	0.5	5
102	Electrophysiological Changes of the Atrium in Patients with Lone Paroxysmal Atrial Fibrillation. Journal of Atrial Fibrillation, 2010, 3, 251.	0.5	0
103	Drug Therapy for Atrial Fibrillation: What Will Its Role Be in the Era of Increasing Use of Catheter Ablation?. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 108-118.	1.2	8
104	Cardioversion for Atrial Fibrillation: Treatment Options and Advances. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 1073-1084.	1.2	22
105	Structural heart disease: Its importance in association with antiarrhythmic drug therapy. Clinical Cardiology, 2009, 17, II-3-II-6.	1.8	1
106	Practical algorithms for pharmacologic management of the post myocardial infarction patient. Clinical Cardiology, 2009, 28, 28-37.	1.8	10
107	Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: A prospective study. American Heart Journal, 2009, 158, 163-169.e3.	2.7	35
108	Dronedronarone For Atrial Fibrillation: Unbridled Enthusiasm Or Just Another Small Step Forward?. Journal of Atrial Fibrillation, 2009, 1, .	0.5	1

#	ARTICLE	IF	CITATIONS
109	QT Prolongation Following Ectopic Beats: Initial Data Regarding The Upper Limit Of Normal With Possible Implications For Antiarrhythmic Therapy And Concealed (Unexpressed) Long QT. Journal of Atrial Fibrillation, 2009, 1, 113.	0.5	1
110	Introduction. American Journal of Cardiology, 2008, 102, 1H-2H.	1.6	0
111	A Contemporary Look at Classic Trials in Atrial Fibrillation: What Do They Really Show and How Might They Apply to Future Therapies?. American Journal of Cardiology, 2008, 102, 3H-11H.	1.6	9
112	GIANT Flutter Waves in ECG Lead V1: a Marker of Pulmonary Hypertension. Journal of Atrial Fibrillation, 2008, 1, 116.	0.5	0
113	Rate Versus Rhythm Control Pharmacotherapy For Atrial Fibrillation: Where are We in 2008?. Journal of Atrial Fibrillation, 2008, 1, 21.	0.5	8
114	The Anticoagulated Atrial Fibrillation Patient Who Requires "Curative" Therapy for Prostate Carcinoma: a Bleeding Conundrum. Journal of Atrial Fibrillation, 2008, 1, 110.	0.5	0
115	New antiarrhythmic drugs for establishing sinus rhythm in atrial fibrillation: What are our therapies likely to be by 2010 and beyond?. American Heart Journal, 2007, 154, 824-829.	2.7	16
116	Adjunctive therapy for recurrent ventricular tachycardia in patients with implantable cardioverter defibrillators. Current Cardiology Reports, 2007, 9, 381-386.	2.9	2
117	Antiarrhythmic drug therapy for atrial fibrillation: Are the guidelines guiding clinical practice?. Clinical Cardiology, 2006, 29, 97-102.	1.8	22
118	Antiarrhythmic Effects of Omega-3 Fatty Acids. American Journal of Cardiology, 2006, 98, 50-60.	1.6	120
119	Atypical Proarrhythmia with Dofetilide: Monomorphic VT and Exercise-Induced Torsade de Pointes. PACE - Pacing and Clinical Electrophysiology, 2005, 28, 877-879.	1.2	15
120	Comparison of Autotriggered Memory Loop Recorders Versus Standard Loop Recorders Versus 24-Hour Holter Monitors for Arrhythmia Detection. American Journal of Cardiology, 2005, 95, 1055-1059.	1.6	122
121	Drug and Drug-Device Therapy in Heart Failure Patients in the Post-COMET and SCD-HeFT Era. Journal of Cardiovascular Pharmacology and Therapeutics, 2005, 10, S45-S58.	2.0	9
122	Clinical pearls in cardiovascular drug therapy: Class effects and individual drug features. Progress in Cardiovascular Diseases, 2004, 47, 1-2.	3.1	0
123	Formulation substitution: A frequently overlooked variable in cardiovascular drug management. Progress in Cardiovascular Diseases, 2004, 47, 3-10.	3.1	8
124	Have sanctioned algorithms replaced empiric judgment in the selection process of antiarrhythmic drugs for the therapy for atrial fibrillation?. Current Cardiology Reports, 2004, 6, 365-370.	2.9	0
125	Is arterial stiffness a contributing factor to atrial fibrillation in patients with hypertension? A preliminary investigation. American Journal of Hypertension, 2004, 17, 213-216.	2.0	16
126	Will direct thrombin inhibitors replace warfarin for preventing embolic events in atrial fibrillation?. Current Opinion in Cardiology, 2004, 19, 58-63.	1.8	13

#	ARTICLE	IF	CITATIONS
127	Clinical pearls in cardiovascular drug therapy: Class effects and individual drug featuresIntroductory comments. <i>Progress in Cardiovascular Diseases</i> , 2004, 47, 1-2.	3.1	0
128	The potential for changing prescribing patterns from warfarin to oral direct thrombin inhibitors: clinical scenarios. <i>Reviews in Cardiovascular Medicine</i> , 2004, 5 Suppl 5, S12-21.	1.4	1
129	The Implantable Cardioverter-Defibrillator. <i>Circulation</i> , 2002, 105, 1022-1024.	1.6	16
130	Microcomplex[mdash]A new incomplete heart block pattern. <i>Journal of Electrocardiology</i> , 2002, 35, 273-278.	0.9	0
131	Issues in the use of generic antiarrhythmic drugs. <i>Current Opinion in Cardiology</i> , 2001, 16, 23-29.	1.8	31
132	Asymptomatic Atrial Fibrillation. <i>Chest</i> , 2001, 119, 628-631.	0.8	2
133	Is it Rational, Reasonable or Excessive, and Consistently Applied? One View of the Increasing FDA Emphasis on Safety First for the Release and Use of Antiarrhythmic Drugs for Supraventricular Arrhythmias. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2001, 6, 333-339.	2.0	1
134	Time Dependent Changes in Duration of Ventricular Repolarization After AV Node Ablation: Insights into the Possible Mechanism of Postprocedural Sudden Death. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2000, 23, 1539-1544.	1.2	9
135	Effects of Aging and Gender on QT Dispersion in an Overtly Healthy Population. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2000, 23, 1121-1126.	1.2	32
136	Generic antiarrhythmics are not therapeutically equivalent for the treatment of tachyarrhythmias11â—Disclosure: This study was not written with support from or discussion with any pharmaceutical manufacturer.. <i>American Journal of Cardiology</i> , 2000, 85, 1151-1153.	1.6	42
137	Drug choices in the treatment of atrial fibrillation. <i>American Journal of Cardiology</i> , 2000, 85, 12-19.	1.6	58
138	Formulation substitution and other pharmacokinetic variability: underappreciated variables affecting antiarrhythmic efficacy and safety in clinical practice. <i>American Journal of Cardiology</i> , 2000, 85, 46-52.	1.6	27
139	Title is missing!. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2000, 4, 17-19.	1.0	0
140	Intravenous Amiodarone in the Management of Atrial Fibrillation. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 1999, 4, 199-204.	2.0	12
141	Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the antiarrhythmics versus implantable defibrillators (AVID) trial. <i>Journal of the American College of Cardiology</i> , 1999, 34, 325-333.	2.8	103
142	Rhythm Management in Atrial Fibrillation-With a Primary Emphasis on Pharmacological Therapy: Part 1. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1998, 21, 590-602.	1.2	27
143	Rhythm Management in Atrial Fibrillation-with a Primary Emphasis on Pharmacological Therapy: Part 2. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1998, 21, 742-752.	1.2	41
144	Rhythm Management in Atrial Fibrillation-With a Primary Emphasis on Pharmacologic Therapy: Part 3. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1998, 21, 1133-1145.	1.2	22

#	ARTICLE	IF	CITATIONS
145	Importance of beta blockade in the therapy of serious ventricular arrhythmias. American Journal of Cardiology, 1998, 82, 91-191.	1.6	90
146	Antiarrhythmic drugs and devices for the management of ventricular tachyarrhythmia in ischemic heart disease. American Journal of Cardiology, 1998, 82, 311-401.	1.6	6
147	Selecting an antiarrhythmic agent for atrial fibrillation should be a patient-specific, data-driven decision. American Journal of Cardiology, 1998, 82, 72N-81N.	1.6	15
148	Impact of structural heart disease on the selection of class III antiarrhythmics for the prevention of atrial fibrillation and flutter. American Heart Journal, 1998, 135, 551-556.	2.7	24
149	Sotalol for Ventricular Tachyarrhythmias: Beta-Blocking and Class III Contributions, and Relative Efficacy Versus Class I Drugs After Prior Drug Failure. American Journal of Cardiology, 1997, 79, 1048-1053.	1.6	29
150	Title is missing!. Journal of Interventional Cardiac Electrophysiology, 1997, 1, 414-416.	1.0	0
151	How Do Physicians Determine When to Perform an "On-Drug" Electrophysiology Study for Efficacy Determination in Patients with Sustained Ventricular Tachyarrhythmias: A Previously Unaddressed Variable That May Affect Efficacy Rates. PACE - Pacing and Clinical Electrophysiology, 1995, 18, 406-416.	1.2	1
152	Electrophysiological Testing of Sinus Node Function: Diagnostic and Prognostic Application-Including Updated Information From Sinus Node Electrograms. PACE - Pacing and Clinical Electrophysiology, 1994, 17, 349-365.	1.2	31
153	âœln the absence of structural heart diseaseâ€¦.âœ•What is it, and why does it matter in antiarrhythmic drug therapy?. American Heart Journal, 1994, 128, 626-629.	2.7	11
154	Optimum duration of transtelephonic ECG monitoring when used for transient symptomatic event detection. Journal of Electrocardiology, 1991, 24, 165-168.	0.9	34
155	The Relationship Between Sinoatrial Conduction Time and Sinus Cycle Length Revisited. Journal of Cardiovascular Electrophysiology, 1990, 1, 290-299.	1.7	1
156	The Duration of the Sinus Node Depolarization on Transvenous Sinus Node Electrograms Can Identify Sinus Node Dysfunction and Can Suggest Its Severity. PACE - Pacing and Clinical Electrophysiology, 1989, 12, 1746-1756.	1.2	7
157	The Duration of Induced Ventricular Tachycardia as Related to Clinically Sustained Ventricular Tachycardia. Journal of Electrophysiology, 1989, 3, 127-134.	0.5	0
158	Drug-Device Interactions: Clinical Considerations. PACE - Pacing and Clinical Electrophysiology, 1985, 8, 369-373.	1.2	42
159	Current Status of Direct Recordings of the Sinus Node Electrogram in Man. PACE - Pacing and Clinical Electrophysiology, 1983, 6, 1143-1150.	1.2	12
160	Effects of digoxin on sinus nodal function before and after vagal blockade in patients with sinus nodal dysfunction. American Journal of Cardiology, 1979, 43, 983-989.	1.6	46